Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in ChinaY-90 SIRT for Unresectable HCC Larger Than 7cm
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 33
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06707233 - No phaseTaking peopleProspective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 500
- Run by
- Sun Yat-sen University
See details and how to joinNCT06788353 - Phase 2Taking peoplePhase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
- Where
- Nanjing, Xuzhou, Yancheng
- Age
- 18 years to 75 years
- People
- 122
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06607276 - Phase 3Not yet taking people in ChinaA Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Where
- Anyang, Bengbu, Guangzhou, Lanzhou, Lishui, Luoyang, Nanjing, Shanghai, Tianjin, Zhengzhou
- Age
- 18 years to 80 years
- People
- 228
- Run by
- InnoBM Pharmaceuticals Co., Ltd.
See details and how to joinNCT06779461 - No phaseTaking peopleTIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 42
- Run by
- Sun Yat-sen University
See details and how to joinNCT06622031 - Phase 2Taking peopleExploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma
- Where
- Fuyang, Hefei
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06664021 - Phase 2Taking peopleTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Sun Yat-sen University
See details and how to joinNCT04615143 - Phase 2Taking peopleStereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 130
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06766643 - Phase 2Taking peopleClinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
- Where
- Nanjing
- Age
- 18 years to 80 years
- People
- 276
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06762782 - Phase 3Taking peopleCamrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years and over
- People
- 130
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT05613478 - Phase 2Taking peopleFruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 36
- Run by
- Sun Yat-sen University
See details and how to joinNCT06446154 - No phaseTaking peopleCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
- Where
- Wuhan
- Age
- 18 years and over
- People
- 50
- Run by
- Tongji Hospital
See details and how to joinNCT06653062 - No phaseTaking peopleCirculating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
- Where
- Wuhan
- Age
- 18 years and over
- People
- 50
- Run by
- Tongji Hospital
See details and how to joinNCT06653127 - No phaseNot yet taking people in ChinaEffect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 84
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06749678 - Phase 1Taking peopleMts105 for Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 14
- Run by
- Shen Lin
See details and how to joinNCT06689540 - No phaseTaking peopleThe Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Ruijin Hospital
See details and how to joinNCT06746194 - Phase 2Taking peopleClinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 33
- Run by
- CNBG-Virogin Biotech (Shanghai) Ltd.
See details and how to joinNCT06746480 - No phaseTaking peopleStudy on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
- Where
- Chenzhou, Guangzhou, Hengyang
- Age
- 18 years to 65 years
- People
- 400
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT06746701 - Phase 1Taking peopleOH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 12
- Run by
- Binhui Biopharmaceutical Co., Ltd.
See details and how to joinNCT05698459 - Phase 2Taking peoplePD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 36
- Run by
- West China Hospital
See details and how to joinNCT06742424 - Phase 2Taking peopleA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
- Where
- Shanghai
- Age
- 18 years and over
- People
- 117
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06349980 - Phase 2/3Not yet taking people in ChinaSBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 398
- Run by
- Sun Yat-sen University
See details and how to joinNCT06739317 - No phaseTaking peopleRecurrent Liver Cancer: Reconceptualization and Reevaluation
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Nanjing Medical University
See details and how to joinNCT06430983 - Phase 2Not yet taking people in ChinaA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 120
- Run by
- Tasly Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06724263 - Phase 2Taking peopleToripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
- Where
- Tianjin
- Age
- 18 years and over
- People
- 70
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06721286